Search results for "MEDICATION"

showing 10 items of 322 documents

Hyperpigmentation of hard palate induced by chloroquine therapy

2017

The antimalarials are one of the most commonly prescribed drugs for conditions such as lupus erythematosus and rheumatoid arthritis, and the side effects, though infrequent, are well known. The antimalarial agent chloroquine diphosphate usually causes pigmentary changes in the oral mucosa characterized by a bluish-grey to black discolorations mainly in the hard palate. Considering only the hard palate hyperpigmentation caused by chloroquine, to the best of our knowledge, only 13 cases have been reported in the English language literature. We described an additional case of palate hyperpigmentation related to the chronic use of chloroquine diphosphate in a 60-year-old Mexican woman. Although…

medicine.medical_specialtyMedication historyCase Report03 medical and health sciences0302 clinical medicineChloroquinemedicineAntimalarial AgentOral mucosaAdverse effectGeneral DentistryOral Medicine and Pathologybusiness.industry030206 dentistrymedicine.disease:CIENCIAS MÉDICAS [UNESCO]HyperpigmentationDermatologymedicine.anatomical_structure030220 oncology & carcinogenesisRheumatoid arthritisUNESCO::CIENCIAS MÉDICASHard palatemedicine.symptombusinessmedicine.drug
researchProduct

Ocrelizumab initiation in patients with MS

2020

ObjectiveTo provide first real-world experience on patients with MS treated with the B cell–depleting antibody ocrelizumab.MethodsWe retrospectively collected data of patients who had received at least 1 treatment cycle (2 infusions) of ocrelizumab at 3 large neurology centers. Patients' characteristics including premedication, clinical disease course, and documented side effects were analyzed.ResultsWe could identify 210 patients (125 women, mean age ± SD, 42.1 ± 11.4 years) who had received ocrelizumab with a mean disease duration of 7.3 years and a median Expanded Disability Status Scale score of 3.75 (interquartile range 2.5–5.5; range 0–8). Twenty-six percent of these patients had a pr…

medicine.medical_specialtyNeurologyExpanded Disability Status Scalebusiness.industryFingolimod03 medical and health sciences0302 clinical medicineNatalizumabNeurologyInterquartile rangeInternal medicinemedicineOcrelizumabObservational studyPremedication030212 general & internal medicineNeurology (clinical)business030217 neurology & neurosurgerymedicine.drugNeurology - Neuroimmunology Neuroinflammation
researchProduct

Does the “Silver Bullet” Lose its Shine Over the Time? Assessment of Loss of Lithium Response in a Preliminary Sample of Bipolar Disorder Outpatients.

2016

Background:Though often perceived as a “silver bullet” treatment for bipolar disorder (BD), lithium has seldom reported to lose its efficacy over the time.Objective:The aim of the present study was to assess cases of refractoriness toward restarted lithium in BD patients who failed to preserve maintenance.Method:Treatment trajectories associated with re-instituted lithium following loss of achieved lithium-based maintenance in BD were retrospectively reviewed for 37 BD-I patients (median age 52 years; F:M=17:20 or 46% of the total) over an 8.1-month period on average.Results:In our sample only 4 cases (roughly 11% of the total, of whom F:M=2:2) developed refractoriness towards lithium after…

medicine.medical_specialtyPediatricsLithium (medication)EpidemiologyRefractory periodMaintenanceDiscontinuation03 medical and health sciences0302 clinical medicinemedicineClinical significanceBipolar disorderDiscontinuation Maintenance Refractoriness TolerancePsychiatryHigh rateSignificant differencemedicine.disease030227 psychiatryDiscontinuationPsychiatry and Mental healthProspective researchPsychologyRefractorineTolerance030217 neurology & neurosurgerymedicine.drug
researchProduct

W05-01 - Rationale and Design of an RCT Comparing “EMC-Strategy” with TAU in Patients with Major Depression - the EMC Trial

2010

IntroductionFor Major Depression, current guidelines recommend treatment durations of 3-8 weeks until optimisation in case of insufficient outcome. Many retrospective studies indicate that improvement (HAMD-17 decrease ≥20%) occurs usually within 10-14 days and that non-improvement after 14 days of treatment is highly predictive for poor clinical outcome.MethodsIn level 1 of the EMC trial, non-improvers after 14 days of antidepressant treatment will be randomised to “early medication change” (EMC) strategy or treatment according to current guidelines (TAU). EMC schedules treatment optimisations on day 15 and day 29 in case of non-improvement. TAU schedules a medication change after 28 days …

medicine.medical_specialtyPediatricsbusiness.industryRetrospective cohort studylaw.inventionMedication changeClinical PracticePsychiatry and Mental healthRandomized controlled triallawMedicineIn patientbusinessPsychiatryDepression (differential diagnoses)European Psychiatry
researchProduct

Pityriasis rosea Gibert triggered by SARS-CoV-2 infection: A case report.

2021

RATIONALE: Pityriasis rosea Gibert is an erythematous-papulosquamous dermatosis that frequently occurs in young adults. The etiopathogenesis of PR is still unknown, but is frequently associated with episodes of upper respiratory tract infections. It is likely that a new viral trigger of pityriasis rosea is the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). PATIENT CONCERNS: We present the case of a female patient in whom the diagnosis of pityriasis rosea led to the investigation and diagnosis of the SARS-CoV-2 infection. The patient presented to the Department of Dermatology for a 3 week duration of an extremely pruritic erythematous-squamous lesion, initially on the trunk …

medicine.medical_specialtyPityriasis RoseaContext (language use)Lesion03 medical and health sciencescoronavirus disease 20190302 clinical medicineAdrenal Cortex HormonesmedicineHumans030212 general & internal medicineClinical Case ReportRespiratory tract infectionsbusiness.industrySARS-CoV-24900COVID-19pityriasis rosea GibertGeneral MedicineMiddle Agedmedicine.diseaseDermatologyRashTopical medicationmedicine.anatomical_structure030220 oncology & carcinogenesisPityriasis roseaEtiologyFemalemedicine.symptombusinessRespiratory tractResearch Articlesevere acute respiratory syndrome coronavirus 2Medicine
researchProduct

ReMindCare, an app for daily clinical practice in patients with first episode psychosis: A pragmatic real-world study protocol.

2021

[EN] Aim Despite the potential benefits of e-health interventions for patients with psychosis, the integration of these applications into the clinical workflow and analysis of their long-term effects still face significant challenges. To address these issues, we developed the ReMindCare app. This app aims to improve the treatment quality for patients with psychosis. We chose to study the app in real world and pragmatic manner to ensure results will be generalizable. Methods This is a naturalistic empirical study of patients in a first episode of psychosis programme. The app was purpose-designed based on two previous studies, and it offers the following assessments: (a) three daily questions…

medicine.medical_specialtyPsychosismedia_common.quotation_subjectPsychological interventionIrritabilitysmartphoneMedication Adherence03 medical and health sciences0302 clinical medicineEmpirical researchmental disordersmedicineCIENCIAS DE LA COMPUTACION E INTELIGENCIA ARTIFICIALElectronic Health RecordsHumansadherencepsychosisPsychiatryappBiological Psychiatrymedia_commonFirst episodeE-healthbusiness.industryEarly Intervention in the Real Worldmedicine.diseasePsychosisMental healthMobile Applications030227 psychiatrySadnessPsychiatry and Mental healthPsychotic DisordersAdherenceAnxietye‐healthSmartphonePshychiatric Mental Healthmedicine.symptombusinessApp030217 neurology & neurosurgeryEarly intervention in psychiatry
researchProduct

Analgesics for Dental Implants: A Systematic Review

2021

Postsurgical pain is commonly associated with dental and oral surgery, and the use of analgesics has been investigated in the management of postoperative pain. This systematic review summarizes available evidence on analgesics used to manage dental implant surgery postoperative pain, to identify best therapeutic protocols and knowledge gap. A comprehensive search was conducted including MEDLINE/Pubmed, EMBASE, SCOPUS, clinicaltrials.gov, and the Cochrane Database of Systematic Reviews through May 2020. Only randomized controlled trials were included. PRISMA guidelines were followed, and risk of bias was appraised using Cochrane RoB2 tool. Eleven trials (762 patients overall) were included. …

medicine.medical_specialtyRandomizationOral surgerymedicine.medical_treatmentMEDLINEPlacebolaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialsystematic reviewlawMedicinePharmacology (medical)painDental implantPharmacologydental implantbusiness.industrylcsh:RM1-950analgesics; dental implant; pain; post-operative pain; systematic review030206 dentistryRescue medicationSystematic reviewpost-operative painlcsh:Therapeutics. PharmacologyPhysical therapyanalgesicsbusiness030217 neurology & neurosurgeryFrontiers in Pharmacology
researchProduct

Adherence, compliance and persistence to oral antineoplastic therapy: a review focused on chemotherapeutic and biologic agents

2011

Introduction: To date, orally administered chemotherapy and biologic agents represent a significant percentage of all antineoplastic treatments in several types of cancer, which are most likely to increase in the near future. In this scenario, the issue of adherence and persistence to oral therapy is a key issue since poor compliance to oral antineoplastic treatments may negatively influence patients' clinical outcomes and, in turn, cause an increase in costs, number of hospitalizations and time spent in the hospital. Areas covered: The issue of adherence to new oral chemotherapeutic and/or biologic agents has not been deeply evaluated and data published in medical literature are quite scar…

medicine.medical_specialtySettore MED/06 - Oncologia MedicaPoor compliancemedicine.medical_treatmentAdministration OralAntineoplastic AgentsPharmacologySocioeconomic FactorMedication AdherencePersistence (computer science)PersistenceAntineoplastic AgentImmunologic FactorNeoplasmsHumansImmunologic FactorsMedicinePharmacology (medical)Intensive care medicineOral therapyCancerChemotherapybusiness.industryCancerHealth Care CostsGeneral MedicineDrug adherencemedicine.diseaseBiologic AgentsHealth Care CostHospitalizationSocioeconomic FactorsAdherenceNeoplasmbusinessOral chemotherapyHumanMedical literatureExpert Opinion on Drug Safety
researchProduct

A pragmatic window of opportunity to minimise the risk of MRONJ development in individuals with osteoporosis on Denosumab therapy: a hypothesis

2021

Abstract Denosumab is associated with the development of medication-related osteonecrosis of the jaw (MRONJ), an uncommon but severe oral side effect with a higher prevalence in metastatic cancer patients than in patients with metabolic bone fragility. Although several oral triggers can initiate MRONJ, invasive oral treatments and tooth extraction still remain the most common precipitating event. In general, tooth extraction and oral surgery should be avoided in patients at increased risk of MRONJ, while extraction of non-restorable teeth should be performed based on specific risk reduction protocols to eliminate dental/periodontal infections, still protecting from MRONJ onset. Based on th…

medicine.medical_specialtySide effectOsteoporosisSpecialties of internal medicine030209 endocrinology & metabolismMRONJOral surgery tooth extraction03 medical and health sciences0302 clinical medicineOral surgeryMedication-related osteonecrosis of the jawmedicineDenosumab osteoporosis; Medication-related osteonecrosis of the jaw; MRONJ; Oral surgery tooth extraction; Denosumab; Diphosphonates; Humans; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; OsteoporosisHumansIntensive care medicineGeneral Dentistrytooth extractionBisphosphonate-associated osteonecrosis of the jawDiphosphonatesBone Density Conservation Agentsbusiness.industryHypothesismedicine.diseaseosteoporosisDenosumab osteoporosisBone Density Conservation Agentsstomatognathic diseasesDenosumabOtorhinolaryngologyRC581-951030220 oncology & carcinogenesisDental surgeryOral and maxillofacial surgeryBisphosphonate-Associated Osteonecrosis of the JawNeurology (clinical)DenosumabbusinessOsteonecrosis of the jawmedicine.drugHead & Face Medicine
researchProduct

Sodium-hydrogen exchange inhibition: novel strategy to prevent myocardial injury following ischemia and reperfusion.

1999

Activation of Na+/H+ exchange and subsequent calcium overload in cardiac myocytes appear to play an important role in myocardial tissue injury following ischemia and reperfusion. Results of several in vitro studies in isolated myocytes and heart preparations and in vivo studies in pigs and rats have suggested that inhibition of Na+/H+ exchange is an effective means to prevent lethal reperfusion injury, arrhythmia, and improve myocardial contractile dysfunction. In patients with acute myocardial infarction (MI), any preventive agent is administered immediately before or shortly after reperfusion, rather than before the occurrence of coronary occlusion. The direct interventional approach to t…

medicine.medical_specialtySodium-Hydrogen Exchangersmedicine.medical_treatmentPremedicationIschemiaMyocardial InfarctionMyocardial Reperfusion InjuryPilot ProjectsGuanidineschemistry.chemical_compoundInternal medicineAngioplastyLactate dehydrogenasemedicineAnimalsHumansMyocardial infarctionSulfonesAngioplasty Balloon CoronaryInfusions IntravenousCariporidebiologybusiness.industrymedicine.diseaseRatschemistryCoronary occlusionAnesthesiaCardiologybiology.proteinCreatine kinaseCardiology and Cardiovascular MedicinebusinessReperfusion injuryAnti-Arrhythmia AgentsThe American journal of cardiology
researchProduct